Cancer News
Articles 61 - 70 of most recent articles
Smoke-Free Policies Effective, Says International Agency For Research On Cancer
Smoke-free policies reduce the exposure of both adults and children, reduce the prevalence of smoking in adults and reduce the risk of heart disease related to smoke exposure. A resulting reduction in the lung cancer burden may well occur as a result of these policies, but relevant evidence will only become available some time in the future. Further, such policies do not negatively affect the restaurant and bar industry.
Medical News Today – Jul 1, 2008 11:00 AM [GMT] ¦ comment?
Smoke-free policies reduce the exposure of both adults and children, reduce the prevalence of smoking in adults and reduce the risk of heart disease related to smoke exposure. A resulting reduction in the lung cancer burden may well occur as a result of these policies, but relevant evidence will only become available some time in the future. Further, such policies do not negatively affect the restaurant and bar industry.
Medical News Today – Jul 1, 2008 11:00 AM [GMT] ¦ comment?
The GI Company Reports Additional Phase II Clinical Data Of Intestinal Trefoil Factor (rhITF) Oral Spray For Oral Mucositis
At the Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology's 2008 International Symposium on Supportive Care in Cancer (MASCC / ISOO) held last week in Houston, Texas, The GI Company reported secondary endpoints relating to Oral Mucositis A
Medical News Today – Jul 1, 2008 10:00 AM [GMT] ¦ comment?
At the Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology's 2008 International Symposium on Supportive Care in Cancer (MASCC / ISOO) held last week in Houston, Texas, The GI Company reported secondary endpoints relating to Oral Mucositis A
Medical News Today – Jul 1, 2008 10:00 AM [GMT] ¦ comment?
Percutaneous Radiofrequency Ablation Shows Promise In The Treatment Of Lung Tumours
Percutaneous radiofrequency ablation - a minimally invasive treatment technique that heats and destroys cancer cells - achieves a high rate of sustained complete responses in selected patients with lung tumours, according to results from the first prospective study of patients treated with technique. Tumours in the lungs are common. Lung cancer is the leading cause of cancer death in both men and women.
Medical News Today – Jul 1, 2008 10:00 AM [GMT] ¦ comment?
Percutaneous radiofrequency ablation - a minimally invasive treatment technique that heats and destroys cancer cells - achieves a high rate of sustained complete responses in selected patients with lung tumours, according to results from the first prospective study of patients treated with technique. Tumours in the lungs are common. Lung cancer is the leading cause of cancer death in both men and women.
Medical News Today – Jul 1, 2008 10:00 AM [GMT] ¦ comment?
$1.5 Million Grant For Nanoparticle Cancer Research
A biomedical engineering assistant professor at The University of Texas at Austin has been awarded a $1.5 million National Institutes of Health/National Cancer Institute grant to conduct nanoparticle cancer research. Grant recipient James Tunnell says the five-year project will include collaboration with other researchers from the university, M.D. Anderson Cancer Center in Houston and the University of California at Irvine.
Medical News Today – Jul 1, 2008 09:00 AM [GMT] ¦ comment?
A biomedical engineering assistant professor at The University of Texas at Austin has been awarded a $1.5 million National Institutes of Health/National Cancer Institute grant to conduct nanoparticle cancer research. Grant recipient James Tunnell says the five-year project will include collaboration with other researchers from the university, M.D. Anderson Cancer Center in Houston and the University of California at Irvine.
Medical News Today – Jul 1, 2008 09:00 AM [GMT] ¦ comment?
The Risk Of Persistent Local Disease In Bladder Cancer Patients Found To Be Pathologic Stage T0 At Radical Cystectomy
ORLANDO, FL (UroToday.com) - Pathologic stage T0 (pT0) rates following radical cystectomy (RC) alone range from 10-15%. The pT0 rate increases in patients that have received neoadjuvant platinum-based chemotherapy. Survival in patients that achieve pT0 status is significantly improved compared to patients with residual invasive disease. Increasingly clinicians are questioning the necessity for RC in patients that can be identified as pT0 in the bladder after chemotherapy.
Medical News Today – Jul 1, 2008 09:00 AM [GMT] ¦ comment?
ORLANDO, FL (UroToday.com) - Pathologic stage T0 (pT0) rates following radical cystectomy (RC) alone range from 10-15%. The pT0 rate increases in patients that have received neoadjuvant platinum-based chemotherapy. Survival in patients that achieve pT0 status is significantly improved compared to patients with residual invasive disease. Increasingly clinicians are questioning the necessity for RC in patients that can be identified as pT0 in the bladder after chemotherapy.
Medical News Today – Jul 1, 2008 09:00 AM [GMT] ¦ comment?
Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint In Phase I/IIa Clinical Trial
Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, announced a status update for its continuing Phase I/IIa Chemophase(R) clinical trial in the treatment of superficial bladder cancer. Based on the results, the Chemophase combination treatment of mitomycin plus the recombinant human hyaluronidase (rHuPH20) enzyme was well tolerated and appears safe.
Medical News Today – Jul 1, 2008 08:00 AM [GMT] ¦ comment?
Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, announced a status update for its continuing Phase I/IIa Chemophase(R) clinical trial in the treatment of superficial bladder cancer. Based on the results, the Chemophase combination treatment of mitomycin plus the recombinant human hyaluronidase (rHuPH20) enzyme was well tolerated and appears safe.
Medical News Today – Jul 1, 2008 08:00 AM [GMT] ¦ comment?
The Mary Kay Ash Charitable Foundation Awards Grant To Fund Innovative Breast Surgery Training Program
The American Society of Breast Disease announces the creation of the Mary Kay Ash Advanced Training Program in Oncoplastic Breast Surgery. The Addison-based Mary Kay Ash Charitable Foundation - a leading philanthropy in the field of cancers affecting women - has approved a two-year $225,000 grant to support this innovative program to train breast surgeons in the emerging field of oncoplastic surgery.
Medical News Today – Jul 1, 2008 07:00 AM [GMT] ¦ comment?
The American Society of Breast Disease announces the creation of the Mary Kay Ash Advanced Training Program in Oncoplastic Breast Surgery. The Addison-based Mary Kay Ash Charitable Foundation - a leading philanthropy in the field of cancers affecting women - has approved a two-year $225,000 grant to support this innovative program to train breast surgeons in the emerging field of oncoplastic surgery.
Medical News Today – Jul 1, 2008 07:00 AM [GMT] ¦ comment?
Cytheris Announces Publication Of IL-7 Oncology Data In The Journal Of Experimental Medicine
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, announced the publication of data from a phase 1 dose escalation study evaluating the effects of IL-7 therapy on human lymphocytes in subjects with non-hematologic, non-lymphoid cancer refractory to standard therapy. The results of this study, performed in collaboration with U.S.
Medical News Today – Jul 1, 2008 07:00 AM [GMT] ¦ comment?
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, announced the publication of data from a phase 1 dose escalation study evaluating the effects of IL-7 therapy on human lymphocytes in subjects with non-hematologic, non-lymphoid cancer refractory to standard therapy. The results of this study, performed in collaboration with U.S.
Medical News Today – Jul 1, 2008 07:00 AM [GMT] ¦ comment?
Promising Cancer Treatment Ready for Human Trial
HealthDay - MONDAY, June 30 (HealthDay News) -- A clinical trial will examinewhether a new cancer treatment is as effective in humans as it's proven tobe in mice, say researchers at Wake Forest University Baptist MedicalCenter in Winston-Salem, N.C.
Yahoo! – Jul 1, 2008 03:46 AM [GMT] ¦ comment?
HealthDay - MONDAY, June 30 (HealthDay News) -- A clinical trial will examinewhether a new cancer treatment is as effective in humans as it's proven tobe in mice, say researchers at Wake Forest University Baptist MedicalCenter in Winston-Salem, N.C.
Yahoo! – Jul 1, 2008 03:46 AM [GMT] ¦ comment?
Orexo Report Abstral (Rapinyl) Approval In Europe
Orexo AB (OMX: ORX), the Swedish pharmaceutical company, announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending approval of Rapinyl, for breakthrough cancer pain. ProStrakan Group plc, the international speciality pharmaceutical is Orexo´s exclusive partner for sales and marketing of Abstral/Rapinyl in Europe.
Medical News Today – Jun 30, 2008 6:00 PM [GMT] ¦ comment?
Orexo AB (OMX: ORX), the Swedish pharmaceutical company, announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending approval of Rapinyl, for breakthrough cancer pain. ProStrakan Group plc, the international speciality pharmaceutical is Orexo´s exclusive partner for sales and marketing of Abstral/Rapinyl in Europe.
Medical News Today – Jun 30, 2008 6:00 PM [GMT] ¦ comment?
